Mirum Pharmaceuticals, Inc.
MIRM
$96.55
$3.914.22%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 54.74% | 53.66% | 62.33% | 69.31% | 80.76% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 54.74% | 53.66% | 62.33% | 69.31% | 80.76% |
| Cost of Revenue | 22.78% | 12.96% | 22.81% | 44.98% | 73.56% |
| Gross Profit | 64.97% | 68.97% | 77.49% | 78.19% | 83.19% |
| SG&A Expenses | 27.10% | 25.14% | 28.62% | 32.85% | 38.62% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.02% | 27.44% | 30.43% | 37.03% | 43.64% |
| Operating Income | 74.73% | 56.45% | 47.36% | 29.64% | 19.74% |
| Income Before Tax | 75.35% | 58.33% | 46.61% | 51.70% | 46.49% |
| Income Tax Expenses | 87.96% | -67.61% | -30.64% | 1.49% | 3.94% |
| Earnings from Continuing Operations | 73.43% | 58.50% | 46.35% | 51.22% | 46.18% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 73.43% | 58.50% | 46.35% | 51.22% | 46.18% |
| EBIT | 74.73% | 56.45% | 47.36% | 29.64% | 19.74% |
| EBITDA | 103.29% | 75.91% | 62.98% | 43.95% | 34.93% |
| EPS Basic | 74.46% | 61.38% | 51.46% | 58.75% | 55.62% |
| Normalized Basic EPS | 76.28% | 14.24% | 5.94% | -13.12% | -9.66% |
| EPS Diluted | 73.60% | 61.14% | 51.43% | 58.72% | 55.61% |
| Normalized Diluted EPS | 75.97% | 13.66% | 5.94% | -13.12% | -9.66% |
| Average Basic Shares Outstanding | 5.27% | 7.63% | 10.09% | 14.62% | 20.09% |
| Average Diluted Shares Outstanding | 8.62% | 11.10% | 10.09% | 14.62% | 20.09% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |